vs
Mativ Holdings, Inc.（MATV）とPrestige Consumer Healthcare Inc.（PBH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Mativ Holdings, Inc.の直近四半期売上が大きい（$463.1M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.6倍）。Mativ Holdings, Inc.の純利益率が高く（21.8% vs 16.5%、差は5.3%）。Mativ Holdings, Inc.の前年同期比売上増加率が高い（1.0% vs -2.4%）。Prestige Consumer Healthcare Inc.の直近四半期フリーキャッシュフローが多い（$75.3M vs $8.0M）。過去8四半期でPrestige Consumer Healthcare Inc.の売上複合成長率が高い（1.2% vs -3.8%）
Mativ Holdings, Inc.は世界的な特殊材料メーカーで、高性能先端ポリマー、不織布、ろ過ソリューション、機能性コーティング材料を製造しています。医療、産業、消費財、航空宇宙、エネルギー分野に顧客を持ち、北米、欧州、アジア太平洋地域で事業を展開しています。
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
MATV vs PBH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $463.1M | $283.4M |
| 純利益 | $100.8M | $46.7M |
| 粗利率 | 18.8% | 55.5% |
| 営業利益率 | 2.2% | 29.1% |
| 純利益率 | 21.8% | 16.5% |
| 売上前年比 | 1.0% | -2.4% |
| 純利益前年比 | 6620.0% | -23.5% |
| EPS（希薄化後） | $1.87 | $0.97 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $463.1M | $283.4M | ||
| Q3 25 | $513.7M | $274.1M | ||
| Q2 25 | $525.4M | $249.5M | ||
| Q1 25 | $484.8M | $296.5M | ||
| Q4 24 | $458.6M | $290.3M | ||
| Q3 24 | $498.5M | $283.8M | ||
| Q2 24 | $523.8M | $267.1M | ||
| Q1 24 | $500.2M | $277.0M |
| Q4 25 | $100.8M | $46.7M | ||
| Q3 25 | $-3.2M | $42.2M | ||
| Q2 25 | $-9.5M | $47.5M | ||
| Q1 25 | $-425.5M | $50.1M | ||
| Q4 24 | $1.5M | $61.0M | ||
| Q3 24 | $-20.8M | $54.4M | ||
| Q2 24 | $-1.4M | $49.1M | ||
| Q1 24 | $-28.0M | $49.5M |
| Q4 25 | 18.8% | 55.5% | ||
| Q3 25 | 19.3% | 55.3% | ||
| Q2 25 | 19.7% | 56.2% | ||
| Q1 25 | 15.0% | 57.3% | ||
| Q4 24 | 16.9% | 55.5% | ||
| Q3 24 | 18.8% | 55.5% | ||
| Q2 24 | 20.8% | 54.7% | ||
| Q1 24 | 16.8% | 54.8% |
| Q4 25 | 2.2% | 29.1% | ||
| Q3 25 | 3.1% | 29.1% | ||
| Q2 25 | 3.8% | 28.8% | ||
| Q1 25 | -88.8% | 29.8% | ||
| Q4 24 | 0.6% | 31.7% | ||
| Q3 24 | 1.4% | 29.7% | ||
| Q2 24 | 2.0% | 27.0% | ||
| Q1 24 | -2.8% | 29.7% |
| Q4 25 | 21.8% | 16.5% | ||
| Q3 25 | -0.6% | 15.4% | ||
| Q2 25 | -1.8% | 19.0% | ||
| Q1 25 | -87.8% | 16.9% | ||
| Q4 24 | 0.3% | 21.0% | ||
| Q3 24 | -4.2% | 19.2% | ||
| Q2 24 | -0.3% | 18.4% | ||
| Q1 24 | -5.6% | 17.9% |
| Q4 25 | $1.87 | $0.97 | ||
| Q3 25 | $-0.06 | $0.86 | ||
| Q2 25 | $-0.18 | $0.95 | ||
| Q1 25 | $-7.82 | $1.00 | ||
| Q4 24 | $0.03 | $1.22 | ||
| Q3 24 | $-0.38 | $1.09 | ||
| Q2 24 | $-0.03 | $0.98 | ||
| Q1 24 | $-0.52 | $0.98 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $84.2M | $62.4M |
| 総負債低いほど良い | $1.0B | $1.0B |
| 株主資本純資産 | $498.7M | $1.8B |
| 総資産 | $2.1B | $3.5B |
| 負債/資本比率低いほどレバレッジが低い | 2.07× | 0.56× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $84.2M | $62.4M | ||
| Q3 25 | $97.1M | $119.1M | ||
| Q2 25 | $95.6M | $139.5M | ||
| Q1 25 | $84.0M | $97.9M | ||
| Q4 24 | $94.3M | $50.9M | ||
| Q3 24 | $162.2M | $51.5M | ||
| Q2 24 | $133.4M | $34.3M | ||
| Q1 24 | $128.9M | $46.5M |
| Q4 25 | $1.0B | $1.0B | ||
| Q3 25 | $1.0B | $993.1M | ||
| Q2 25 | $1.1B | $992.7M | ||
| Q1 25 | $1.1B | $992.4M | ||
| Q4 24 | $1.1B | $992.0M | ||
| Q3 24 | $1.2B | $1.1B | ||
| Q2 24 | $1.2B | $1.1B | ||
| Q1 24 | $1.2B | $1.1B |
| Q4 25 | $498.7M | $1.8B | ||
| Q3 25 | $397.4M | $1.8B | ||
| Q2 25 | $416.6M | $1.9B | ||
| Q1 25 | $428.2M | $1.8B | ||
| Q4 24 | $858.5M | $1.8B | ||
| Q3 24 | $882.3M | $1.7B | ||
| Q2 24 | $898.0M | $1.7B | ||
| Q1 24 | $906.9M | $1.7B |
| Q4 25 | $2.1B | $3.5B | ||
| Q3 25 | $2.0B | $3.4B | ||
| Q2 25 | $2.1B | $3.4B | ||
| Q1 25 | $2.1B | $3.4B | ||
| Q4 24 | $2.4B | $3.3B | ||
| Q3 24 | $2.6B | $3.3B | ||
| Q2 24 | $2.6B | $3.3B | ||
| Q1 24 | $2.7B | $3.3B |
| Q4 25 | 2.07× | 0.56× | ||
| Q3 25 | 2.63× | 0.54× | ||
| Q2 25 | 2.66× | 0.54× | ||
| Q1 25 | 2.67× | 0.54× | ||
| Q4 24 | 1.30× | 0.55× | ||
| Q3 24 | 1.32× | 0.61× | ||
| Q2 24 | 1.29× | 0.65× | ||
| Q1 24 | 1.30× | 0.68× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.3M | $78.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.0M | $75.3M |
| FCFマージンFCF / 売上 | 1.7% | 26.6% |
| 設備投資強度設備投資 / 売上 | 2.4% | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 0.19× | 1.68× |
| 直近12ヶ月FCF直近4四半期 | $93.8M | $267.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.3M | $78.3M | ||
| Q3 25 | $72.8M | $57.5M | ||
| Q2 25 | $57.6M | $79.0M | ||
| Q1 25 | $-15.9M | $61.8M | ||
| Q4 24 | $24.1M | $65.1M | ||
| Q3 24 | $37.6M | $69.8M | ||
| Q2 24 | $46.1M | $54.8M | ||
| Q1 24 | $-13.0M | $66.9M |
| Q4 25 | $8.0M | $75.3M | ||
| Q3 25 | $66.7M | $55.4M | ||
| Q2 25 | $48.9M | $78.2M | ||
| Q1 25 | $-29.8M | $58.4M | ||
| Q4 24 | $2.0M | $63.5M | ||
| Q3 24 | $25.5M | $67.8M | ||
| Q2 24 | $37.4M | $53.6M | ||
| Q1 24 | $-25.1M | $63.8M |
| Q4 25 | 1.7% | 26.6% | ||
| Q3 25 | 13.0% | 20.2% | ||
| Q2 25 | 9.3% | 31.3% | ||
| Q1 25 | -6.1% | 19.7% | ||
| Q4 24 | 0.4% | 21.9% | ||
| Q3 24 | 5.1% | 23.9% | ||
| Q2 24 | 7.1% | 20.1% | ||
| Q1 24 | -5.0% | 23.0% |
| Q4 25 | 2.4% | 1.1% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 1.7% | 0.3% | ||
| Q1 25 | 2.9% | 1.2% | ||
| Q4 24 | 4.8% | 0.5% | ||
| Q3 24 | 2.4% | 0.7% | ||
| Q2 24 | 1.7% | 0.4% | ||
| Q1 24 | 2.4% | 1.1% |
| Q4 25 | 0.19× | 1.68× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.66× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | 16.07× | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | — | 1.35× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
